Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.35 |
| ▸ | NNMT | P40261 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211576 | 0.70 | NNMT (0.45) | SIRT6NNMTLMNA | |
| SCHEMBL3286589 | 0.64 | SIRT6 (0.47) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL27894794 | 0.62 | ADORA3 (0.36) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL2635320 | 0.62 | SIRT6 (0.73) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL19928751 | 0.60 | NNMT (0.49) | ADORA3TSHRMC4RADRA1AMC3R | |
| Hydrochloric Acid SCHEMBL27917292 | 0.60 | SIRT6 (0.70) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL31434970 | 0.59 | SIRT6 (0.35) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL30521607 | 0.59 | ADORA3 (0.42) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL7581332 | 0.59 | SIRT6 (0.46) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL30441778 | 0.59 | SIRT6 (0.46) | ADORA3TSHRMC4RADRA1AMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | ADORA3 1738/4885TSHR 2194/4885MC4R 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.